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INTRODUCTION
Despite timely and complete reperfusion by primary percutaneous coronary intervention (PCI), mortality and morbidity are still high in patients with large ST-segment elevation myocardial infarction (STEMI) [1] . Data from animal models suggested that the process of restoring coronary blood flow itself paradoxically induces myocardial injury and contributes to final infarct size (IS) [2] [3] [4] . This phenomenon is called "reperfusion injury" (RI) and it is thought to mitigate the full benefit of reperfusion [2] [3] [4] . Although several aspects remain obscure and definitive evidence in humans is lacking, experimental studies have established that altered mitochondrial function is strongly involved in the RI genesis [4] [5] . As such, several randomized clinical trials (RCT) assessed the effectiveness of novel agents capable of targeting mitochondrial function with the aim to reduce IS and improve outcome [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . These studies have reported conflicting results using surrogate markers and none was individually adequately powered for hard endpoints [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Systematic reviews employing meta-analytic techniques provide quantitative and objective means to pool and assess available clinical evidence, emphasizing internal validity and homogeneity, while affording increased statistical power for hypothesis testing. Thus, the aim of this study was to perform a systematic review and meta-analysis of RCTs comparing drugs targeting mitochondrial function vs. placebo in patients undergoing primary PCI for STEMI.
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METHODS
We developed a systematic review and meta-analysis following Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) amendment to the Quality of Reporting of Metaanalyses (QUOROM) statement [20] [21] [22] [23] . The protocol for this study was previously published on an international prospective register for systematic reviews (PROSPERO) with the number:
CRD42016033085.
Search strategy
Two expert cardiologists (RP, SB) independently and systematically searched (MESH strategy) MEDLINE, Cochrane Library, Google Scholar and Biomed Central for RCTs comparing drugs against the RI vs. placebo in patients with STEMI. The terms searched were: (reperfusion injury)
AND ((PCI) OR (percutaneous coronary intervention) OR (ST elevation myocardial infarction) OR
(STEMI) OR (myocardial infarction)). Details of the search strategy are reported in the appendix online. The research was carried out in December 2015.
Selection criteria
Shortlisted studies were retrieved as full articles and appraised independently by two unblinded reviewers (GC, FO), with divergences resolved after consensus, according to the following inclusion criteria: i) English language; ii) enrollment of STEMI patients; iii) reperfusion strategy by primary PCI; iv) randomized treatment allocation; v) comparison of agent/drug against RI vs.
placebo/gold standard treatment; vi) at least 50 patients. Exclusion criteria were: i) duplicate reports failing to report additional or extended clinical outcomes, ii) lack of outcome data beyond hospitalization; iii) equivocal or non-random treatment allocation. Finally, selected studies were analysed by two independent reviewers (PP, GM) to establish if the experimental drug did or did
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not have a mechanism of action targeting mitochondrial function (detailed description in the supplemental appendix). They checked the following items for each drug/agent: pharmacological targets, location or not of the targets in mitochondria, activation or not of mitochondrial pathways, selectivity and exclusivity in the action against mitochondria. This adjudication was performed according to a recent overview [5] and after revision of all available information regarding the agent/drug. The studies were classified into three groups: i) direct/selective mechanism of action targeting a mitochondrial component/pathway; ii) indirect/unspecific mechanism of action targeting mitochondrial component/pathway; and iii) mechanism of action not targeting mitochondria. The present study focused its attention on the first two groups.
Data abstraction, endpoints, contact with authors
The reviewers (RP, SB, GC, FO) independently abstracted data. In the case of incomplete or unclear data, authors were contacted obtaining missing information. In addition, for the studies of Jones et al. and Lonborg et al., a longer follow-up was available (36 vs. 12 months and 12 vs. 1 months, respectively) and it was included in our analysis [16] [17] . The primary endpoint of the analysis was the incidence of cardiovascular death. Secondary endpoints were: all-cause death, hospital readmission for heart failure (HF) and left ventricular ejection fraction (LVEF). We performed a pre-hoc stratification of studies according to mechanism of action (direct/selective vs. indirect/unspecific). Additional analyses were performed after stratification of studies according to the following criteria:
i) administration of cyclosporine, ii) administration of nicorandil, iii) follow-up length <12
vs. ≥12 months iv) indirect/unspecific drugs after exclusion of the study of Pizarro et al. [15] .
Internal validity and quality appraisal
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Two unblinded reviewers (RP, SB) evaluated the quality of included studies using prespecified electronic forms that were piloted over the first 3 cases. No studies were excluded on the basis of this analysis. The same authors independently verified the eventual exclusion of some studies analyzing references from all the papers. Modifying the MOOSE item list in order to take into account the specific features of included studies, we separately abstracted and appraised study design, setting and data sources. Hence, following the Cochrane Collaboration approach we evaluated for each RCT the risk of analytical, selection, adjudication, detection, and attrition bias (expressed as low, moderate, or high risk of bias, as well as incomplete reporting leading to inability to ascertain the underlying risk of bias).
Data analysis and synthesis
Continuous variables were reported as mean (±SD) or median [interquartile range].
Categorical variables were expressed as number and percentage. The endpoints were expressed as an odds ratio (OR). Point estimates and standard errors were calculated and combined by the generic inverse variance method [24] , computing risk estimates with 95%
confidence intervals according to logarithmic transformation of the hazard measures.
Considering the high likelihood of between-study variance, we used a random effect model. Statistical heterogeneity was assessed using the Cochran's Q test. This statistic was complemented with the I 2 statistic, which quantifies the proportion of total variation across studies that is due to heterogeneity rather than chance. A value of I 2 of 0 to 25 % represents insignificant heterogeneity, 26 to 50 % low heterogeneity, 51 to 75 % moderate heterogeneity, and >75 % high heterogeneity [25] . To test the difference between subgroup analyses the Chi 2 test has been used. Finally, random effect meta-regression analysis was performed to assess the effect of several potential confounding factors (sex, anterior MI, glycoprotein IIb/IIa inhibitor, baseline TIMI flow 0-1, smoking, dyslipidemia, prior
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MI, stent implantation, thrombus-aspiration, diabetes, hypertension) on results. Publication bias was appraised by graphical valuation of funnel plots and through Begg and Mazumdar rank correlation, Egger's regression intercept, and Duval and Tweedie trim and fill [26] .
Prometa (Internovi, Cesena, Itay) and RevMan 5 (The Cochrane Collaboration, The
Nordic Cochrane Centre, Copenhagen, Denmark) software were used for statistical analyses.
RESULTS
Search results and study selection
The database search yielded 948 citations (Figure 1 ). Shortlisted citations were retrieved and checked at the title/abstract level excluding 889 papers (Figure 1 ). Complete articles for the remaining 45 studies were checked for compliance to inclusion/exclusion criteria ( Figure 1 ). Finally, we identified 25 eligible trials meeting our inclusion/exclusion criteria of which 10 were excluded because the experimental drug was not targeting mitochondria. A total of 15 studies were included in qualitative and quantitative metaanalysis ( [9, 15] (see online supplemental for more details). Finally, they decided to classify the first as direct/selective mechanism of action and to include the second, but as indirect/unspecific mechanism of action.
Baseline characteristics
Overall, 5864 patients were randomized and 5680 (97%) patients were included in the final analysis (Table 1) . Six studies randomized 1774 subjects to treatment with an experimental drug with direct/selective mechanism of action against mitochondrial component/pathways (Table 1) . Three studies used cyclosporine, whereas in 3 studies other drugs were administered (delcasertib, MTP-131, TRO40303). Conversely, 9 studies randomized 1329 patients to an experimental drug with an indirect/unspecific mechanism of action against mitochondrial component/pathways (metoprolol, atrial natriuretic peptide, nicorandil, exenatide, doxycycline, nitrite). The mean age of the population was 61±1 years old (Table 1) . Anterior MI was present in 3802 (66%) patients. Baseline TIMI
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flow grade was 0-1 in 4693 (82%) patients. The use of glycoprotein IIb/IIIa inhibitors and thromboaspiration was relatively common (37% and 35% of patients, respectively).
Cardiovascular mortality
Overall, the pooled effect estimate analysis showed a non-significant reduction in cardiovascular mortality (OR 0.9, 95%CI 0.7-1.17, p=0.4, I 2 =10%) in patients randomly allocated to receive drugs targeting mitochondrial function (Figure 2 (Figure 3 ).
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Additional analyses
Additional analyses are detailed in the online appendix. Briefly, the administration of cyclosporine or nicorandil vs. placebo did not affect study outcomes (see Figure 1 and 2 in Ref [27] ). A reduction in hospital readmission for HF was more evident in studies with follow-up length ≥12 months (see Figure 4 , 5 and 6 in Ref [27] ). Excluding the study by Pizarro et al. (metoprolol) [15], we did not observe significant differences in our results (see Figure 3 in Ref [27] ). Finally, random effects meta-regression disclosed no significant interaction between confounding factors and the administration of drugs targeting mitochondrial function and outcomes (Supplemental Table 3 ). Especially, baseline TIMI flow >1, thromboaspiration and glycoprotein IIbIIIa inhibitor did not affect the relationship between experimental drug and outcome.
Publication bias
There was no evidence of publication bias (supplemental online).
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DISCUSSION.
In the last decades, we observed a significant and progressive mortality reduction in STEMI patients receiving coronary reperfusion by primary PCI [1] . Nevertheless, mortality after STEMI is still not negligible and the number of patients developing HF is increasing [1] [2] [3] 28] . In addition, all of these trials were underpowered for hard clinical endpoints. The reasons for this failure are multiple and not the aim of our study [28] . Surely, discrepancies in the dose of the experimental drug, of the timing of its administration and of the patient's selection (e.g. location of MI, spontaneous coronary reperfusion, time between symptom's onset and reperfusion) played a crucial role in these mixed or neutral results [29] .
The purpose of the present meta-analysis was to collect data from each RCT to assess the presence of benefit on hard endpoints deriving from the administration of experimental drug against mitochondrial component/pathways. The strengths of our work are the selection of agents, the adjudication of the mechanism of action by experts in the field of mitochondrial function, the collection of original data from authors, the largest sample size for a study in this topic and the low
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degree of heterogeneity (expressed as I 2 %) in the majority of the analyses. Overall, we did not demonstrate a significant reduction in either cardiovascular or all-cause mortality. The administration of experimental drugs targeting mitochondrial function in STEMI patients did not affect mortality. This neutral effect was observed despite the significant improvement in LVEF and the reduction in HF hospital readmissions. We may speculate that the benefit in terms of LVEF preservation and HF reduction is too small to translate into a mortality advantage or that the study population and/or the number of deaths are not adequate to observe a significant difference. In addition, we have a follow-up length >12 months only in 7 studies and the short follow-up could be limited the benefit in terms of mortality due to HF hospital readmission reduction.
The major novelty of our work is the focus on drugs targeting mitochondrial function. This is the first attempt to classify drugs according the mechanism of action against mitochondria and to investigate their effectiveness. The pathophysiological rationale derives from previous and recent studies suggesting that most critical subcellular signalling of lethal RI are located in mitochondria components and/or pathways [4] [5] . Interestingly, we did not observe any benefit from the administration of drugs with a mechanism of action direct and selective for mitochondrial targets.
Conversely, drugs with a broad-spectrum mechanism of action reduced all clinical endpoints, including cardiovascular and all-cause mortality. Furthermore, the findings were also confirmed after the exclusion of the study by Pizarro et al. where patients were randomized to metoprolol vs.
placebo (questionable effect against mitochondrial targets) [15] . These findings could be interpreted as indirect evidence against RI. We may infer that RI is not important or that it is not a major determinant of prognosis in humans. Nicorandil, exenatide, metoprolol, nitrite, doxycycline and atrial natriuretic peptide have multiple physiological effects which could have improved LVEF or reduced mortality and HF, independently from any effect on RI [12] [13] [14] [15] [16] [17] [18] [19] . Alternatively, the results of this study could be viewed as proof against mitochondrial involvement in RI. Nevertheless, we may hypothesize that the targets of drugs with presumed direct/selective mechanisms of action against mitochondria were in fact not directed primarily at key factors in the RI genesis, as recent evidence
suggest for cyclosporine and TRO40303 [4, [30] [31] . Finally, our findings should be also interpreted in context with the results from mechanical strategies of cardioprotection (post and remote conditioning) [32] . We cannot exclude that components and pathways involved in myocardial necrosis during myocardial ischemia and reperfusion are multiple. Accordingly, a broad-spectrum approach (e.g. the recently proposed "combination reperfusion therapy") could be more effective as compared to a single-target approach [5] . Besides such intriguing speculations, further studies are clearly warranted either in pre-clinical and clinical setting [29] [30] [31] [32] [33] [34] .
Study limitations
Our results suffer from those limitations which are inherent to all meta-analytic techniques including particularly heterogeneity in patient populations, different study drug regimens, and variable endpoint definitions across studies. This mainly applies to the different criteria employed to assess IS. Due to variable definitions and methods (cardiac magnetic resonance, troponin T or I or creatine kinase release) across studies, we are not able to give a comprehensive estimate of effect on IS. In addition, despite the inclusion of 15 studies, our final study population (5680 STEMI patients) remains underpowered to draw final conclusions on mortality. Consequently, subgroup analyses should be considered hypothesis-generating and require further confirmations. Finally, since non-fatal endpoints were included in the analysis, competing risk should be accounted for in the analysis, but data to calculate them were not available.
Conclusions
Administration of drugs targeting mitochondrial function in STEMI patients undergoing primary PCI appear to have no effect on mortality, but may reduce hospital readmission for HF. The drugs with a broad-spectrum mechanism of action seem to be more effective in reducing adverse events. 
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